To provide further data on this safety concern, we used nationwide registers in Sweden, Denmark and Norway to assess the association of use of DPP4 inhibitors and GLP-1-receptor agonists with risk of cholangiocarcinoma. Here, DPP4 is linked to cholangiocarcinoma.